Teva Pharmaceutical Industries (NYSE:TEVA) Rating Lowered to “Hold” at StockNews.com

Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.

Other analysts also recently issued research reports about the company. Piper Sandler boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. Barclays dropped their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. UBS Group dropped their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Finally, Bank of America dropped their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus target price of $23.43.

Teva Pharmaceutical Industries Trading Down 0.1 %

Shares of TEVA stock opened at $15.34 on Friday. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries has a 1 year low of $12.51 and a 1 year high of $22.80. The stock has a fifty day moving average of $18.85 and a two-hundred day moving average of $18.38. The firm has a market capitalization of $17.40 billion, a PE ratio of -10.58, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, research analysts expect that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.55% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Oarsman Capital Inc. purchased a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at $29,000. Marshall & Sterling Wealth Advisors Inc. purchased a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at $44,000. Smithfield Trust Co grew its holdings in shares of Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after buying an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at $50,000. Finally, Venturi Wealth Management LLC purchased a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at $60,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.